Tuba Öcek Baş

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza et al. · Journal of Clinical Oncology · 2020 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Luis Paz‐Ares, David Vicente, Ali Tafreshi et al. · Journal of Thoracic Oncology · 2020 · 645 citations · Full text

Medicine, Oncology, Pharmacology +14

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · Zurich Open Repository and Archive (University of Zurich) · 2022 · 557 citations

Pharmacy, Oncology, Pharmacotherapy +17

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio et al. · Journal of Clinical Oncology · 2022 · 162 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · Journal of Clinical Oncology · 2021 · 156 citations

Medicine, Oncology, Pharmacotherapy +17